B-cell depletion in the treatment of lupus nephritis

Nature Reviews Nephrology

Volumn 8, Issue 9, 2012, Pages 505-514

  Gregersen, Jon W ^a   Jayne, David R W ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATACICEPT; AZATHIOPRINE; BELIMUMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPRATUZUMAB; GLUCOCORTICOID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PLACEBO; RITUXIMAB; STEROID;

ABSENCE OF SIDE EFFECTS; ANCA ASSOCIATED VASCULITIS; B LYMPHOCYTE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIFE EXPECTANCY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIORITY JOURNAL; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSION; LUPUS NEPHRITIS; LYMPHOCYTE DEPLETION; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84865479037     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.141     Document Type: Review

References (81)

1. Rahman, A. & Isenberg, D. A. Systemic lupus erythematosus. N. Engl. J. Med. 358, 929-939 (2008
2. Bagavant, H. & Fu, S. M. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr. Opin. Rheumatol. 21, 489-494 (2009
3. Manzi, S. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J. Epidemiol. 145, 408-415 (1997
4. Björnådal, L., Yin, L., Granath, F., Klareskog, L. & Ekbom, A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-1995. J. Rheumatol. 31, 713-719 (2004
5. Gourley, M. F. et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med. 125, 549-557 (1996
6. Flanc, R. S. et al. Treatment of diffuse proliferative lupus nephritis: A meta-Analysis of randomized controlled trials. Am. J. Kidney Dis. 43, 197-208 (2004
7. Dey, I. D. & Isenberg, D. A. Systematic review and meta-Analysis of the association of systemic lupus erythematosus and malignancy [abstract]. Arthritis Rheum. 63, 2283 (2011). 8. Cameron, J. S. Lupus nephritis: An historical perspective 1968-1998. J. Nephrol. 12, S29-S41 (1999).
8. Christopher-Stine, L. et al. Renal biopsy in lupus patients with low levels of proteinuria. J. Rheumatol. 34, 332-335 (2007
9. Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 15, 241-250 (2004
10. Borchers, A. T., Keen, C. L., Shoenfeld, Y. & Gershwin, M. E. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun. Rev. 3, 423-453 (2004
11. Cervera, R. et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82, 299-308 (2003
12. Tesar, V. & Hruskova, Z. Treatment of proliferative lupus nephritis: A slowly changing landscape. Nat. Rev. Nephrol. 7, 96-109 (2011
13. Houssiau, F. A. et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46, 2121-2131 (2002
14. Ginzler, E. M. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219-2228 (2005
15. Chan, T. M. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou nephrology study group. N. Engl. J. Med. 343, 1156-1162 (2000
16. Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103-1112 (2009
17. Chan, T. M., Tse, K. C., Tang, C. S., Mok, M. Y. & Li, F. K. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 16, 1076-1084 (2005
18. Ciruelo, E., de la Cruz, J., López, I. & Gómez Reino, J. J. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum. 39, 2028-2034 (1996
19. Moroni, G. et al. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol. Dial. Transplant. 22, 2531-2539 (2007
20. Mosca, M. et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 61, 1502-1509 (2002
21. Illei, G. G. et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow-up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 46, 995-1002 (2002
22. Houssiau, F. A. et al. The 10-year follow-up data of the Euro-Lupus nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheum. Dis. 69, 61-64 (2010
23. Clatworthy, M. R. & Smith, K. G. B cells in glomerulonephritis: focus on lupus nephritis. Semin. Immunopathol. 29, 337-353 (2007
24. Arce-Salinas, C. A., Rodríguez-García, F. & Gómez-Vargas, J. I. Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis. Rheumatol. Int. 32, 1245-1249 (2012
25. Jónsdóttir, T., Sundelin, B., Welin Henriksson, E., van Vollenhoven, R. F. & Gunnarsson, I. Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits. Ann. Rheum. Dis. 70, 1172-1173 (2011
26. Pepper, R. et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol. Dial. Transplant. 24, 3717-3723 (2009
27. Boletis, J. N. et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: A long-term prospective study. Nephrol. Dial. Transplant. 24, 2157-2160 (2009
28. Melander, C. et al. Rituximab in severe lupus nephritis: Early Bcell depletion affects long-term renal outcome. Clin. J. Am. Soc. Nephrol. 4, 579-587 (2009
29. Li, E. K. et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford) 48, 892-898 (2009
30. Gunnarsson, I. et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56, 1263-1272 (2007
31. Vigna-Perez, M. et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res. Ther. 8, R83 (2006
32. Sfikakis, P. P. et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum. 52, 501-513 (2005
33. Vital, E. M. et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 63, 3038-3047 (2011
34. Roccatello, D. et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol. Dial. Transplant. 26, 3987-3992 (2011
35. Terrier, B. et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum. 62, 2458-2466 (2010
36. Catapano, F., Chaudhry, A. N., Jones, R. B., Smith, K. G. & Jayne, D. W. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol. Dial. Transplant. 25, 3586-3592 (2010
37. Garcia-Carrasco, M. et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: A longitudinal analysis of 52 Hispanic patients. Lupus 19, 213-219 (2010
38. Lateef, A., Lahiri, M., Teng, G. G. & Vasoo, S. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus 19, 765-770 (2010
39. Lu, T. Y. et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients. Arthritis Rheum. 61, 482-487 (2009
40. Lindholm, C. et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J. Rheumatol. 35, 826-833 (2008
41. Jónsdóttir, T. et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann. Rheum. Dis. 67, 330-334 (2008
42. Tanaka, Y. et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod. Rheumatol. 17, 191-197 (2007
43. Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R. & Isenberg, D. A. Bcell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology (Oxford) 44, 1542-1545 (2005
44. Looney, R. J. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580-2589 (2004
45. Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum. 64, 1215-1226 (2012
46. Mysler, E. F. et al. Efficacy and safety of ocrelizumab, a humanized antiCD20 antibody, in patients with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III BELONG study [abstract]. Arthritis Rheum. 62, 1455 (2010
47. Bomback, A. S. & Appel, G. B. Updates on the treatment of lupus nephritis. J. Am. Soc. Nephrol. 21, 2028-2035 (2010
48. Rezvani, A. R. & Maloney, D. G. Rituximab resistance. Best Pract. Res. Clin. Haematol. 24, 203-216 (2011
49. Genovese, M. C. et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 58, 2652-2661 (2008
50. Morschhauser, F. et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann. Oncol. 21, 1870-1876 (2010
51. Rigby, W. et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a fortyeightweek randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 64, 350-359 (2012
52. US National library of Medicine. Study of the safety of MDX1342 in combination with methotrexate in patients with rheumatoid arthritis (MDX1342-1301). Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT00639834.
53. Traczewski, P. & Rudnicka, L. Treatment of systemic lupus erythematosus with epratuzumab. Br. J. Clin. Pharmacol. 71, 175-182 (2011).
54. Dörner, T. et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8, R74 (2006
55. Jacobi, A. M. et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann. Rheum. Dis. 67, 450-457 (2008
56. Leonard, J. P. et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 113, 2714-2723 (2008
57. Moisini, I. & Davidson, A. BAFF: A local and systemic target in autoimmune diseases. Clin. Exp. Immunol. 158, 155-163 (2009
58. Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 377, 721-731 (2011
59. Dooley, M. A. et al. Effect of belimumab treatment on renal outcomes: results from phase 3 belimumab clinical trials in patients with systemic lupus erythematosus [abstract]. Arthritis Rheum. 63, 2472 (2011)
60. Pena-Rossi, C. et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18, 547-555 (2009
61. US National library of Medicine. Atacicept phase II/III in generalized systemic lupus erythematosus (April SLE). Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00624338?term=1.
62. Jónsdóttir, T. et al. Clinical improvements in proliferative vs membranous lupus nephritis following Bcell depletion: pooled data from two cohorts. Rheumatology (Oxford) 49, 1502-1504 (2010
63. Díaz-Lagares, C. et al. The UKBIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun. Rev. 11, 357-364 (2012
64. Dooley, M. A. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886-1895 (2011
65. Houssiau, F. A. et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann. Rheum. Dis. 69, 2083-2089 (2010
66. Contreras, G. et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350, 971-980 (2004
67. Laskari, K., Mavragani, C. P., Tzioufas, A. G. & Moutsopoulos, H. M. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: A long-term observational prospective study. Arthritis Res. Ther. 12, R208 (2010
68. Smith, K. G. & Clatworthy, M. R. FcgammaRIIB in autoimmunity and infection: Evolutionary and therapeutic implications. Nat. Rev. Immunol. 10, 328-343 (2010
69. Niederer, H. A., Clatworthy, M. R., Willcocks, L. C. & Smith, K. G. FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. Ann. NY Acad. Sci. 1183, 69-88 (2010
70. Lim, S. H. et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118, 2530-2540 (2011
71. Turner-Stokes, T. et al. The efficacy of repeated treatment with Bcell depletion therapy in systemic lupus erythematosus: An evaluation. Rheumatology (Oxford) 50, 1401-1408 (2011
72. Calabrese, L. H., Molloy, E. S., Huang, D. & Ransohoff, R. M. Progressive multifocal leukoencephalopathy in rheumatic diseases: Evolving clinical and pathologic patterns of disease. Arthritis Rheum. 56, 2116-2128 (2007
73. Tak, P. P. et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a fortyeightweek randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 64, 360-370 (2012
74. Stohl, W. et al. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: The phase III FILM trial. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2011-200706.
75. Petri, M. et al. Randomized controlled trials of epratuzumab (anti-CD22 mAb targeting B cells) reveal clinically meaningful improvements in patients with moderate/severe SLE flares [abstract]. Ann. Rheum. Dis. 67, 53 (2008
76. Wallace, D. et al. Randomized controlled trials of epratuzumab (anti-CD22 mAb targeting B cells) reveal clinically meaningful reductions in corticosteroid use with favorable safety profile in moderate and severe flaring SLE patients [abstract]. Ann. Rheum. Dis. 67, 212 (2008
77. Strand, V. et al. Randomized controlled trials of epratuzumab (anti-CD22 mAb targeting B cells) reveal clinically meaningful improvements in health related quality of life in SLE patients with high disease activity and low baseline self-report measures [abstract]. Ann. Rheum. Dis. 67, 212 (2008
78. Wallace, D. J. et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study [abstract]. Arthritis Rheum. 62, 1452 (2010
79. Kalunian, K. C. et al. BILAG-measured improvement in moderately and severely affected body systems in patients with systemic lupus erythematosus (SLE) by epratuzumab: results from EMBLEM, a phase IIb study [abstract]. Arthritis Rheum. 62, 453 (2010
80. US National library of Medicine. Study of epratuzumab in systemic lupus erythematosus. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT00383513?term=NCT00383513&rank1.
81. Rhee, E. P., Laliberte, K. A. & Niles, J. L. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-Associated vasculitis. Clin. J. Am. Soc. Nephrol. 5, 1394-1400 (2010).